Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study.
Yanaika S Hok-A-HinKatharina BolsewigDaimy N RuitersAlberto LleóDaniel AlcoleaAfina W LemstraWiesje Maria van der FlierCharlotte E TeunissenMarta Del Campo MilanPublished in: Alzheimer's & dementia (Amsterdam, Netherlands) (2023)
Validation of our proteomics findings underpins the potential of CSF THOP1 as an early specific biomarker associated with AD pathology. The use of antibody-based platforms in both the discovery and validation phases facilitated the translation of proteomics findings, providing an additional workflow that may accelerate the development of biofluid-based biomarkers.